1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Genentech Hemophilia Therapy Gets Solid Endorsement From ICER

 
• By Cathy Kelly

Hemlibra could save health care system $1.85m per patient annually as it displaces current approaches to treatment, Institute for Clinical and Economic Review projects in draft report.

Genentech Inc.'s recently-approved therapy to prevent bleeding in a small subgroup of hemophilia patients, Hemlibra (emicizumab-kxwh), offers significantly improved efficacy and savings to the health care system compared to existing treatments, the Institute for Clinical and Economic Review concludes in a draft report.

"The findings of our analysis suggest that emicizumab prophylaxis provides gains in quality-adjusted life years at substantially lower costs over a lifetime horizon, with these findings remaining robust across multiple sensitivity and scenario analyses," ICER notes. The draft report, released Jan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Market Access

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.